OncoZenge AB (8LY) AI Stock Analysis

OncoZenge AB

(Frankfurt:8LY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthRevenue growth indicates improving commercialization traction and expanding product adoption, even from a small base. If this trend continues, higher sales could provide operating leverage and gradually improve the company’s ability to fund development and market expansion.

Negative Factors

Persistent Large LossesLarge recurring losses show that the current cost base remains far above the company’s revenue scale. Without continued revenue growth or meaningful expense control, persistent losses can erode financial resources and limit the company’s ability to invest independently.

OncoZenge AB (8LY) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 7.80M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -1.6
Beta (1Y): 0.61
Revenue Growth: 122.10%
EPS Growth: -242.46%
Country: Germany
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

OncoZenge AB Business Overview & Revenue Model

Company Description

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinica...

OncoZenge AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:8LY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ISOFOL	49Neutral	SEK 383.95M	-5.99	-54.41%	―	―	32.79%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:ONCO	47Neutral	SEK 721.66M	-2.14	―	―	87.23%	35.27%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%

* Healthcare Sector Average

Performance Comparison

DE:8LY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:8LY	OncoZenge AB	0.26	-0.13	-33.85%
SE:ONCO	Oncopeptides AB	1.67	-3.75	-69.16%
SE:ISOFOL	Isofol Medical AB	1.20	0.51	74.89%
SE:ELIC	Elicera Therapeutics AB	2.65	-3.44	-56.47%
SE:IMMU	Immunicum AB	5.50	-1.89	-25.58%
SE:CANTA	Cantargia AB	1.60	-1.97	-55.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

OncoZenge AB AI Stock Analysis